Related Experiment Videos
Chemotherapy for recurrent disease and combined modality therapies for head and neck cancer
1Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Abstract:
The identification and development of new agents and innovative treatment approaches remain a priority. The prognosis for patients with recurrent or metastatic head and neck cancer remains poor; thus participation in trials of promising investigational agents is an important option for these individuals. For patients with locally advanced tumors, combined modality treatment is undergoing rapid evolution. The optimal combination and sequence of therapies have yet to be determined. However, available data support an increasing role for chemotherapy especially as part of strategies to preserve organ function and treat unresectable disease.
Insights
Developing new treatments for head and neck cancer is crucial. Investigational agents and chemotherapy are important options for patients with recurrent, metastatic, or locally advanced head and neck cancer.
Area of Science:
- Oncology
- Head and Neck Cancer Research
Background:
- The prognosis for recurrent or metastatic head and neck cancer is poor.
- New treatment strategies are urgently needed.
Purpose of the Study:
- To highlight the importance of investigational agents and innovative treatments for head and neck cancer.
- To discuss the evolving role of combined modality treatment for locally advanced tumors.
Main Methods:
- Review of current treatment approaches and emerging therapies for head and neck cancer.
- Analysis of data supporting the role of chemotherapy in managing advanced disease.
Main Results:
- Participation in clinical trials offers a vital option for patients with poor prognosis.
- Chemotherapy plays an increasing role, particularly in organ preservation and unresectable cases.
Conclusions:
- Continued research into novel agents and treatment combinations is essential.
- Chemotherapy is a key component in evolving treatment paradigms for head and neck cancer.